Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.

Gao, Lei; Hong, Zhi-Nuan; Wu, Long; Yang, Yinghong; Kang, Mingqiang

Gao, Lei; Hong, Zhi-Nuan; Wu, Long; Yang, Yinghong; Kang, Mingqiang.

Afiliación

Gao L; Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Hong ZN; Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, China.
Wu L; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.
Yang Y; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China.
Kang M; Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.

Front Immunol ; 13: 1008681, 2022.

Article en En | MEDLINE | ID: mdl-36569913

Asunto(s)

Carcinoma de Células Escamosas; Neoplasias Esofágicas; Carcinoma de Células Escamosas de Esófago; Humanos; Carcinoma de Células Escamosas de Esófago/terapia; Carcinoma de Células Escamosas de Esófago/patología; Neoplasia Residual; Neoplasias Esofágicas/tratamiento farmacológico; Neoplasias Esofágicas/patología; Terapia Neoadyuvante/métodos; Carcinoma de Células Escamosas/patología; Membrana Mucosa/patología

Palabras clave

esophageal squamous cell carcinoma; neoadjuvant immunochemotherapy; regression model; residual tumor; wait and see

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas / Carcinoma de Células Escamosas de Esófago Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google